Corresponding Authors: Yiqun Jiang, MD (firstname.lastname@example.org), and Hao Chen, MD (email@example.com), Department of Dermatopathology, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, #12 Jiangwangmiao Rd, Nanjing, Jiangsu 210042, China.
Published Online: July 21, 2022. doi:10.1001/jamaoncol.2022.2558
Conflict of Interest Disclosures: None reported.
Funding/Support: This work was supported by CAMS Innovation Fund for Medical Sciences (2021-I2M-C&T-B-087).
Role of the Funder/Sponsor: The funder had no role in the preparation, review, or approval of the manuscript and decision to submit the manuscript for publication.
Additional Contributions: We thank the patient for granting permission to publish this information. We also thank Jianfang Sun, MD, from the Department of Dermatopathology, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, for giving advice about diagnosing this case. This individual was not compensated.
RA , Bashey
S , Wysong
A , Kim
J , Kim
YH , Gratzinger
D . Intravascular ALK-negative anaplastic large cell lymphoma with localized cutaneous involvement and an indolent clinical course: toward recognition of a distinct clinicopathologic entity. Am J Surg Pathol
. 2013;37(4):617-623. doi:10.1097/PAS.0b013e318280aa9cPubMedGoogle ScholarCrossref
YN , Wang
Z , Sun
JF , Chen
H . Primary cutaneous anaplastic large-cell lymphoma with 6p25.3 rearrangement exhibits a biphasic histopathologic pattern: two case reports and literature review. J Cutan Pathol
. 2021;48(12):1463-1470. doi:10.1111/cup.14089PubMedGoogle ScholarCrossref
MA , Su
A , Ra
et al. Intralymphatic cutaneous anaplastic large cell lymphoma/lymphomatoid papulosis: expanding the spectrum of CD30-positive lymphoproliferative disorders. Am J Surg Pathol
. 2014;38(9):1203-1211. doi:10.1097/PAS.0000000000000217PubMedGoogle ScholarCrossref
S , O’Connor
OA , Pro
et al; ECHELON-2 Study Group. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet
. 2019;393(10168):229-240. doi:10.1016/S0140-6736(18)32984-2PubMedGoogle ScholarCrossref